Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 100

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 100
---
4 and 2023 the Company issued 125,793 and 75,608 common shares under the ESPP, respectively, at an average price per share of $4.17 and $9.11, respectively. Cash received from purchases under the ESPP for the years ended December 31, 2024 and 2023 was $0.5 million and $0.7 million, respectively. In February 2025, the Company issued 73,239 common shares under the ESPP at an average price per share of $1.08.The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows: 

        Year Ended December 31,

        2024

        2023

        Risk-free interest rate

        5.13
        %

        5.29
        %

        Expected term (in years)

        0.50

        0.50

        Expected volatility

        76.32
        %

        58.38
        %

        Expected dividend yield

        0.00
        %

        0.00
        %
       
      The weighted average grant date fair value of common shares offered and issued under the ESPP during the years ended December 31, 2024 and 2023 was $1.66 and $3.27, respectively.Option Plan and 2020 Plan In December 2016, as further amended in December 2017 and September 2019, the Company adopted the Repare Therapeutics Inc. Option Plan (the “Option Plan”) for the issuance of stock options and other share-based awards to 

120

directors, officers, employees or consultants. The Option Plan authorized up to 4,074,135 shares of the Company’s common shares to be issued. In June 2020, the Company’s board of directors adopted, and the Company’s shareholders approved the 2020 Equity Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on the effective date of the IPO, at which time the Company ceased making awards under the Option Plan. The 2020 Plan allows the Company’s compensation committee to make equity-based and cash-based incentive awards to the Company’s officers, employees, directors and consultants including but not limited to stock options and restricted share units. The aggregate number of common shares reserved and available for issuance under the 2020 Plan has automatically increased on January